Pharmigene’s Genetic Test for Carbamazepine Response Now Standard in 50 Taiwan Hospitals
April 13, 2011
Pharmigene’s Genetic Test for Carbamazepine Response Now Standard in 50 Taiwan Hospitals
Pharmigene said last week that 50 hospitals in Taiwan will now administer its test for HLA-B*1502, which is a marker for increased risk of adverse events in Asian populations treated with the anti-seizure drug carbamazepine.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pharmigene Licenses IP to Mayo Clinic for Companion Dx for Stevens-Johnson Syndrome
November 17, 2010 / GenomeWeb Daily News - Dx Focus: Clarient to Offer Qiagen Therascreen KRAS Test as Erbitux CDx
January 31, 2013 / PCR Insider - Qiagen Expands Companion Dx Portfolio with Three Licensing Deals; Exceeds 2012 QiaSymphony Placement Target
January 7, 2013 / GenomeWeb Daily News - Clovis Pulls Plug on Personalized Cancer Drug after Trial Shows No Benefit for Drug or Marker
November 14, 2012 / Pharmacogenomics Reporter - AB Science, Skuldtech Developing Companion Dx to Predict Masitinib Response in Pancreatic Cancer
November 14, 2012 / Pharmacogenomics Reporter